<DOC>
	<DOC>NCT02486809</DOC>
	<brief_summary>This study will assess the bioequivalence in healthy participants between a high-concentration formulation of lebrikizumab withdrawn from a vial and administered SC as a single injection by a needle and syringe, and a low-concentration formulation of lebrikizumab administered SC as a single injection via PFS-NSD.</brief_summary>
	<brief_title>A Bioequivalence Study of Subcutaneous (SC) Lebrikizumab Administered by Needle and Syringe or by Prefilled Syringe With Needle Safety Device (PFS-NSD)</brief_title>
	<detailed_description />
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Healthy adults 18 to 65 years of age, inclusive Body mass index (BMI) 18 to 32 kg/m^2 and body weight 50 to 100 kg, inclusive Nonpregnant and nonlactating females Agreement to utilize effective contraception among men and women of childbearing potential Known allergy or hypersensitivity to study drug or components History of alcohol or drug abuse within 12 months prior to study drug, or positive test for alcohol or drugs of abuse Receipt of an investigational agent within 30 days of 5 halflives prior to Day 1 Biological therapy within 90 days prior to Day 1 Parasitic or Listeria monocytogenes infection within 6 months prior to Screening Receipt of blood products within 2 months prior to study entry Donation or loss of blood/plasma within up to 6 months prior to study drug, depending upon volume Receipt of live attenuated vaccine within 1 month prior to study drug Use of tobacco or nicotinecontaining products within 14 days prior to Screening Use of any prescription or nonprescription medication within 14 days prior to study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>